03:23
Highlights from DDW2024: A Discussion on Improving Management of Non-Dysplastic Barrettâs Esophagus
34:38
A Case-Based Discussion on Improving Management of Non-Dysplastic Barrettâs Esophagus (DDW 2024)
01:00:54
Cases with Castle Biosciences: Dr. Witkowski
00:56
Dr. Desiree Ratner - DecisionDx-SCC
03:24
Interview with Dr. Daniel Tseng: The Power of Risk Stratification for Barrett's Esophagus
01:40
A Behind-the-Scenes Look at the TissueCypher Lab Process
28:29
[Webinar] Learn How TissueCypher Uses Spatialomics to Accurately Predict Risk in Barrett's Esophagus
03:43
This is Castle Biosciences. Empowering people, informing care decisions.
04:41
Interview with Dr. Harshit Khara: How does TissueCypher affect Barrettâs esophagus management?
04:05
From fear to confidence: DecisionDx-Melanoma. Gregâs story of empowerment over a melanoma diagnosis
22:46
Obstacles to Cancer Prevention in Barrett's Esophagus 2023
02:59
TissueCypher enables risk-aligned management of patients with non-dysplastic Barrettâs esophagus
05:33
Don't let fear define your journey: a uveal melanoma patient journey
01:33
New data for DecisionDx-Melanoma
14:06
Cases with Castle Biosciences â Angela Wingfield, M.D
14:09
Using Molecular Diagnostics to Inform Cancer Management Decisions / by Matthew Goldberg at PMWC 2023
04:58
Uveal Melanoma Animated Video Castle Bioscience DecisionDx-UM
41:13
New Technology for Managing Non-Dysplastic Barrett's Esophagus (DDW 2023)
01:02:45
Cases with Castle Biosciences - Hadas Skupsky, M.D. FAAD
58:50
IMPACT Melanoma Webinar OnDemand
01:03
AJCC Staging and DecisionDx-Melanoma
57:51
Cases with Castle Biosciences - Etan Marks, DO
44:44
Cases with Castle Biosciences - Barry White, M.D.
50:06
Cases with Castle Biosciences - Drazen Jukic, M.D., Ph.D.
04:58
DecisionDx-UM: Predicting Metastatic Risk for Early-Stage Uveal Melanoma
03:37
Interview with Dr. Lucas C. Duits: Standardizing Patient Management with TissueCypher
10:29
Interview with Dr. Raman Muthusamy: Barrett's Conundrum
21:10
[Webinar / MAGIC] Updates in Screening and Surveillance for Barrettâs Esophagus
13:32
[Webinar] TissueCypher Objectively Risk Stratifies BE Patients with Low-Grade Dysplasia
13:15
[Webinar] Pooled Analysis Using TissueCypher to Predict Progression in Barrett's Esophagus
54:06
[Webinar / EndoscopyNow] Establishing Individual Patient Risk for Progression to Esophageal Cancer
14:26
[Webinar / ASGE] Risk Stratification and Management of Dysplastic Barrettâs Esophagus
59:42
[Webinar / EndoscopyNow] Predicting Progression in Barrettâs Esophagus: Recent Advances
17:20
Interview with Dr. Sri Komanduri, re: the 2022 AGA Clinical Practice Update
19:53
Interview and Research Highlights with Dr. Jacques Bergman
03:59
Understand the Risk of Esophageal Cancer Progression
03:59
TissueCypher Barrett's Esophagus Assay Technology Identifies Potential Esophageal Cancer
33:01
Dermpath on Demand: Utility of Gene Expression Profiling in Melanocytic Lesions
05:07
Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story
49:25
Precision Oncology: DecisionDxÂŽ-Melanoma and the Evolution of GEP Testing in Cutaneous Melanoma
04:20
A Life-Changing Prognosis of Uveal Melanoma: Kevin's Story
34:14
Webinar, Goldberg: Spatialomics & TissueCypher in Todayâs Clinical Management of Barrettâs Esophagus
48:30
Melanoma and the Role of Personalized Medicine: A Dermatologist/Dermatopathologistâs Perspective
33:47
AHNS DecisionDxâSCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients
21:12
CDO - Highly accurate & objective tests for melanocytic lesions of uncertain malignant potential
04:56
Castle Biosciences: Our Story
05:16
Dr. Goldberg - Comprehensive Diagnostic Offering
04:15
Skin Cancer Screening: Derek Maetzold speaks to Sonoran Living
07:17
Katherina Alsina, PhD - Castle Biosciences Genomic Testing for Uveal Melanoma
49:45
D. Patterson, PA-C: Use of GEP to Inform Management Decisions of Skin Cancer Patients
44:49
Dr. Goldberg - Diagnostic & Prognostic Testing in Melanoma and Cutaneous Squamous Cell Carcinoma
30:41
Dr. Sligh - Incorporating Prognostic Gene Expression Profiling in the Management of Skin Cancer
32:22
Dr. Ibrahim - Advances in Cutaneous Squamous Cell Carcinoma
21:57
Dr. Farberg - Implementation of Gene Expression Profiling in the Management of Melanoma
44:56
Dr. Farberg - Integrating Genomics Into Your Clinical Practice
11:11
Dr. Hyams - 40 GEP Cutaneous Squamous Cell Carcinoma
31:36
Dr. Moody - Advances in Cutaneous Melanoma
44:39
Dr. Trotter - GEP: Molecular Information for Personalized Management Decisions in Melanoma and cSCC
31:29
Dr. Sligh - Revolutionizing Gene Expression Profiling in Clinical Management of Skin Cancer
29:27
Dr. Goldberg & Dr. Cook - Diagnostic & Prognostic Testing in Melanocytic Lesions
X
About
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping people first â the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors.
Our innovative tests for skin cancers, uveal melanoma, and Barrettâs esophagus provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. Please visit us at castletestinfo.com/ to learn more about our portfolio of innovative prognostic and diagnostic tests.
Tags